Chinese expert consensus on whole-process management of chemotherapy-related diarrhea(2025 edition)
10.19401/j.cnki.1007-3639.2025.06.011
- VernacularTitle:化疗相关腹泻全程管理中国专家共识(2025年版)
- Author:
Rongbo LIN
;
Yong LIU
;
Ning LI
;
Suxia LUO
- Collective Name:China Anti-Cancer Association Committee of Rehabilitation and Palliative Care;Fujian Anti-Cancer Association Committee of Cancer Pain
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Diarrhea;
Adverse reaction;
Whole-process management;
Consensus
- From:
China Oncology
2025;35(6):605-629
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy is a critical treatment modality for cancer,playing an essential role in oncology.However,chemotherapy-related diarrhea(CRD)remains a troubling adverse effect,often leading to reduced chemotherapy doses,treatment delays or discontinuation,and modifications to therapeutic plans.In severe cases,CRD can be life-threatening.5-fluorouracil and irinotecan are the most common chemotherapy drugs that cause CRD.With the increase in the use of triplet combination chemotherapy regimens,diarrhea-related deaths have increased,which may be related to neutropenic enterocolitis.Loperamide is the main drug for the treatment of CRD.In clinical practice,management of diarrhea that is not responsive to loperamide is of utmost concern.Therefore,based on evidence-based medicine and clinical practice experience,the expert panel carried out a comprehensive assessment and discussion on the definition,pathogenesis,classification,evaluation,diagnosis,intervention,and prevention of CRD.Eventually,the Chinese Expert Consensus on Whole-process Management of Chemotherapy-Related Diarrhea(2025 Edition)was formulated to further standardize the whole-process management of chemotherapy-related diarrhea.The consensus has been registered on Practice guideline REgistration for transPAREncy(PREPARE)with the registration number PREPARE-2024CN1246.
